This review found second-generation antipsychotics were not superior to placebo as augmentation for refractory generalised anxiety disorder. Despite issues with adverse effects and tolerability, quetiapine monotherapy was efficacious compared to placebo for uncomplicated generalised anxiety disorder. The reported data appeared to support the review conclusions, but the paucity of data and study limitations suggest a cautious interpretation is required.
Study selection
Randomised double-blind placebo or active comparator trials of mixed or flexible doses of second-generation antipsychotics for generalised anxiety disorder in adults (>18 years) were eligible for inclusion in the review metaanalysis. Open label trials were summarised in the review. Eligible patients needed a primary diagnosis of generalised anxiety disorder. Patients with other Axis I and Axis II disorders were included unless specified in the individual study protocol. Studies that exclusively assessed adults older than 65 years old were excluded.
Included augmentation studies were for refractory generalised anxiety disorder and assessed quetiapine (120mg/day), risperidone (1.1mg/day) and olanzapine (87mg/day). Failed previous treatments were antidepressant with or without benzodiazepine that lasted four to 12 weeks. All of the monotherapy trials assessed quetiapine and all of these except one assessed different doses of between 50mg/day and 300mg/day; one study used flexible doses (mean dose 125mg/day). Study duration ranged from six to 12 weeks.
Mean dose of second-generation antipsychotic (where reported) ranged from 1.12mg/day to 386mg/day. All studies except one defined generalised anxiety disorder according to the Diagnostic and Statistical Manual Fourth Edition, Text Revision (2000) . Duration of illness was often not defined. Reported mean durations ranged from 11.4 to 24.9 years. Included patients had mostly received at least six to 12 weeks of antidepressant with or without benzodiazepine. Primary outcomes were: clinically significant response, mostly defined as number of participants with a reduction of at least 50% from baseline in Hamilton Anxiety Rating Scale (HAM-A); remission (mostly defined as HAM-A score of 7 or less); and all-cause discontinuation. Secondary outcomes included change in HAM-A.
Two authors selected the studies for inclusion. Disagreements were resolved through discussion.
Assessment of study quality
Study quality was assessed using the Cochrane Collaboration Risk of Bias tool. The authors did not report how many reviews performed the validity assessment.
Data extraction
Intention-to-treat data were used to calculate relative risks (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes and mean differences for continuous outcomes.
Methods of synthesis
Studies were grouped according to comparison and outcome. For monotherapy, comparison patients who received 150mg/day were combined; an additional study used flexible doses. Pooled relative risks and mean differences, with 95% CIs, were calculated using a random-effects analysis. Number needed to treat (NNT) and number needed to harm (NNH) were calculated where relevant. The level of statistical heterogeneity was assessed using Χ 2 and I 2 . Heterogeneity was defined as statistically significant where I 2 was greater than 50%.
Where significant heterogeneity was detected, further analyses were planned a priori to identify outliers by excluding each individual study in sequence. Other planned a priori analyses included effects of different doses of quetiapine XR, patient gender, duration, illness severity and presence of psychiatric comorbidity. Tests of interaction were performed with two-tailed significance set at 0.05.
A funnel plot to assess publication bias was planned a priori, but there were too few studies.
Results of the review
Nine RCTs (2,295 participants) were included in the meta-analysis. Eight open-label non-comparative studies met the inclusion criteria and were described in supplemental tables (available online). The overall quality of the augmentation studies was low. Quality was unclear for the monotherapy studies (only one of four studies could be assessed).
Augmentation studies (five RCTs, 912 participants): There was no statistically significant difference between secondgeneration antipsychotics and placebo for clinical response and remission. There was a significant increase in risk of allcause discontinuation associated with second-generation antipsychotics (RR 1.43, 95% CI 1.04 to 1.96). There were no statistically significant differences between second-generation antipsychotics and placebo for change in Hamilton Anxiety Rating Scale score from baseline and with weight gain.
Monotherapy studies (four RCTs, 1,383 participants): A statistically significant difference in clinical response was reported in favour of second-generation antipsychotics in comparison with placebo (RR 1.31, 95% CI 1.20 to 1.44). Statistically significant differences in favour of second-generation antipsychotics were reported for remission (RR 1.44, 95% CI 1.23 to 1.68) and reduction in Hamilton Anxiety Rating Scale score (RR 3.66, 95% CI 5.13 to 2.19; one RCT). However, in comparison with placebo there was a statistically significant increase in risk of all-cause discontinuation (RR 1.30, 95% CI 1.09 to 1.54) and weight gain (2.2lb, 95% CI 1.16 to 3.24; one RCT). There was no evidence of significant statistical heterogeneity.
Further data reported in the review included a summary of data from open-label studies.
